Book contents
- 50 Big Debates in Reproductive Medicine
- Series page
- 50 Big Debates in Reproductive Medicine
- Copyright page
- Contents
- Contributors
- Foreword
- Introduction
- Section I Limits for IVF
- Section II IVF Add-ons
- Section III The Best Policy
- Section IV Embryology
- Section V Ethics and Statistics
- Section VI Male-factor Infertility
- Section VII Genetics
- 38A Genome Editing Should Be Allowed for the Prevention of Life-Threatening Genetic Diseases
- 38B Genome Editing Should Be Allowed for the Prevention of Life-Threatening Genetic Diseases
- 39A PGT-A Should Be Offered for Recurrent Implantation Failure
- 39B PGT-A Should Be Offered for Recurrent Implantation Failure
- 40A PGT-A Should Be Offered for All Women
- 40B PGT-A Should Be Offered for All Women
- Section VIII Ovarian Stimulation
- Section IX Hormones and the Environment
- Index
- References
40A - PGT-A Should Be Offered for All Women
For
from Section VII - Genetics
Published online by Cambridge University Press: 25 November 2021
Book contents
- 50 Big Debates in Reproductive Medicine
- Series page
- 50 Big Debates in Reproductive Medicine
- Copyright page
- Contents
- Contributors
- Foreword
- Introduction
- Section I Limits for IVF
- Section II IVF Add-ons
- Section III The Best Policy
- Section IV Embryology
- Section V Ethics and Statistics
- Section VI Male-factor Infertility
- Section VII Genetics
- 38A Genome Editing Should Be Allowed for the Prevention of Life-Threatening Genetic Diseases
- 38B Genome Editing Should Be Allowed for the Prevention of Life-Threatening Genetic Diseases
- 39A PGT-A Should Be Offered for Recurrent Implantation Failure
- 39B PGT-A Should Be Offered for Recurrent Implantation Failure
- 40A PGT-A Should Be Offered for All Women
- 40B PGT-A Should Be Offered for All Women
- Section VIII Ovarian Stimulation
- Section IX Hormones and the Environment
- Index
- References
Summary
PGT-A and its use remains a contentious issue within the world of reproductive medicine. It confers many advantages, and we argue that it should be offered to all.
- Type
- Chapter
- Information
- 50 Big Debates in Reproductive Medicine , pp. 205 - 206Publisher: Cambridge University PressPrint publication year: 2021
References
Verpoest, W, Staessen, C, Bossuyt, PM, et al. Preimplantation genetic testing for aneuploidy by microarray analysis of polar bodies in advanced maternal age: a randomized clinical trial. Hum Reprod. 2018;33(9):1767–76.CrossRefGoogle ScholarPubMed
Scott, RT, Upham, KM, Forman, EJ, Zhao, T, Treff, NR. Cleavage-stage biopsy significantly impairs human embryonic implantation potential while blastocyst biopsy does not: a randomized and paired clinical trial. Fertil Steril. 2013;100(3):624–30.CrossRefGoogle Scholar
Dahdouh, EM, Balayla, J, García-Velasco, JA. Comprehensive chromosome screening improves embryo selection: a meta-analysis. Fertil Steril. 2015;104(6):1503–12.CrossRefGoogle ScholarPubMed
Maxwell, SM, Grifo, JA. Should every embryo undergo preimplantation genetic testing for aneuploidy? A review of the modern approach to in vitro fertilization. Best Pract Res Clin Obstet Gynaecol. 2018;53:38–47.CrossRefGoogle ScholarPubMed
Sacchi, L, Albani, E, Cesana, A, et al. Preimplantation genetic testing for aneuploidy improves clinical, gestational, and neonatal outcomes in advanced maternal age patients without compromising cumulative live-birth rate. J Assist Reprod Genet. 2019;36(12):2493–504.CrossRefGoogle ScholarPubMed